Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor

Neuroscience Letters

Volumn 510, Issue 2, 2012, Pages 138-142

  Iravani, Mahmoud M ^a   Sadeghian, Mona ^a   Leung, Clement C M ^a   Jenner, Peter ^a   Rose, Sarah ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Astrocytes; Glial cell line derived neurotrophic factor (GDNF); Interleukin 1 (IL 1 ); Lipopolysaccharide (LPS); Substantia nigra; Tumour necrosis factor (TNF )

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; UPREGULATION;

ANIMALS; ASTROCYTES; ENCEPHALITIS; FLUORESCENT ANTIBODY TECHNIQUE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIOSIS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84856770572     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.01.022     Document Type: Article

References (44)

1. Anastasia A., de Erausquin G.A., Wojnacki J., Masco D.H. Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease. J. Neurochem. 2007, 103:1542-1552.
2. Appel E., Kolman O., Kazimirsky G., Blumberg P.M., Brodie C. Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. Neuroreport 1997, 8:3309-3312.
3. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76:77-98.
4. Bresjanac M., Antauer G. Reactive astrocytes of the quinolinic acid-lesioned rat striatum express GFRalpha1 as well as GDNF in vivo. Exp. Neurol. 2000, 164:53-59.
5. Castano A., Herrera A.J., Cano J., Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 1998, 70:1584-1592.
6. Chen L.W., Zhang J.P., Kwok-Yan Shum D., Chan Y.S. Localization of nerve growth factor, neurotrophin-3, and glial cell line-derived neurotrophic factor in nestin-expressing reactive astrocytes in the caudate-putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/Bl mice. J. Comp. Neurol. 2006, 497:898-909.
7. Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., Johnson J.A. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2933-2938.
8. Choi-Lundberg D.L., Bohn M.C. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Brain Res. Dev. Brain Res. 1995, 85:80-88.
9. Gao H.M., Liu B., Hong J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 2003, 23:6181-6187.
10. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., Carvey P.M., Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 2002, 133:27-35.
11. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
12. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
13. Inoue T., Tsui J., Wong N., Wong S.Y., Suzuki F., Kwok Y.N. Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment. Brain Res. 1999, 826:306-308.
14. Iravani M.M., Costa S., Jackson M.J., Tel B.C., Cannizzaro C., Pearce R.K., Jenner P. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets. Eur. J. Neurosci. 2001, 13:597-608.
15. Iravani M.M., Kashefi K., Mander P., Rose S., Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002, 110:49-58.
16. Iravani M.M., Leung C.C., Sadeghian M., Haddon C.O., Rose S., Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur. J. Neurosci. 2005, 22:317-330.
17. Iravani M.M., Sadeghian M., Leung C.C., Tel B.C., Rose S., Schapira A.H., Jenner P. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp. Neurol. 2008, 212:522-531.
18. Klegeris A., McGeer E.G., McGeer P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol. 2007, 20:351-357.
19. Kramer E.R., Aron L., Ramakers G.M., Seitz S., Zhuang X., Beyer K., Smidt M.P., Klein R. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 2007, 5:e39.
20. Kuno R., Yoshida Y., Nitta A., Nabeshima T., Wang J., Sonobe Y., Kawanokuchi J., Takeuchi H., Mizuno T., Suzumura A. The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res. 2006, 1116:12-18.
21. Lang A.E., Langston J.W., Stoessl A.J., Brodsky M., Brooks D.J., Dhawan V., Elias W.J., Lozano A.M., Moro E., Nutt J.G., Stacy M., Turner D., Wooten G.F. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol. 2006, 5:200-202.
22. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 1999, 46:598-605.
23. Liberatore G.T., Wong J.Y., Porritt M.J., Donnan G.A., Howells D.W. Expression of glial cell line-derived neurotrophic factor (GDNF) mRNA following mechanical injury to mouse striatum. Neuroreport 1997, 8:3097-3101.
24. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
25. Marchetti B., Abbracchio M.P. To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol. Sci. 2005, 26:517-525.
26. Marco S., Canudas A.M., Canals J.M., Gavalda N., Perez-Navarro E., Alberch J. Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum. Exp. Neurol. 2002, 174:243-252.
27. McGeer P.L., Itagaki S., McGeer E.G. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 1988, 76:550-557.
28. McNaught K.S., Jenner P. Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release. Neurosci. Lett. 2000, 285:61-65.
29. Mirza B., Hadberg H., Thomsen P., Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000, 95:425-432.
30. Mogi M., Togari A., Tanaka K., Ogawa N., Ichinose H., Nagatsu T. Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci. Lett. 2000, 289:165-168.
31. Nagatsu T., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J. Neural Transm. Suppl. 2000, 143-151.
32. Ossola B., Schendzielorz N., Chen S.H., Bird G.S., Tuominen R.K., Mannisto P.T., Hong J.S. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GNDF in astroglia. Neuropharmacology 2011, 61:574-582.
33. Paxinos G., Watson C. The Rat Brain: In Stereotaxic Coordinates 1998, Academic Press.
34. Remy S., Naveilhan P., Paille V., Brachet P., Neveu I., Lipopolysaccharide TNFalpha regulate the expression of GDNF, neurturin and their receptors. Neuroreport 2003, 14:1529-1534.
35. Rothwell N.J., Luheshi G.N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000, 23:618-625.
36. Saavedra A., Baltazar G., Duarte E.P. Interleukin-1beta mediates GDNF up-regulation upon dopaminergic injury in ventral midbrain cell cultures. Neurobiol. Dis. 2007, 25:92-104.
37. Saavedra A., Baltazar G., Santos P., Carvalho C.M., Duarte E.P. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol. Dis. 2006, 23:533-542.
38. Schaar D.G., Sieber B.A., Dreyfus C.F., Black I.B. Regional and cell-specific expression of GDNF in rat brain. Exp. Neurol. 1993, 124:368-371.
39. Song Y.J., Halliday G.M., Holton J.L., Lashley T., O'Sullivan S.S., McCann H., Lees A.J., Ozawa T., Williams D.R., Lockhart P.J., Revesz T.R. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J. Neuropathol. Exp. Neurol. 2009, 68:1073-1083.
40. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
41. Visanji N.P., Orsi A., Johnston T.H., Howson P.A., Dixon K., Callizot N., Brotchie J.M., Rees D.D. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2008, 22:2488-2497.
42. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
43. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35:419-432.
44. Yurek D.M., Fletcher-Turner A. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res. 2001, 891:228-235.